[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-detail-363712-en":59,"doc-seo-363712-105":99},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":5,"data":60},{"doc_id":61,"user_id":62,"nickname":63,"user_avatar":64,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":66,"doc_content":67,"file_id":68,"file_url":69,"file_type":70,"file_size":71,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":72,"language":73,"language_code":74,"site_id":75,"html_lang":74,"table_of_contents":76,"faqs":77,"seo_title":78,"seo_description":66,"update_tm":79,"read_time":80,"preview_page_count":19,"preview_urls":81},363712,2336478951081,"Ben ","https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","CXCL14 Promotes Osteosarcoma Cell Migration and Invasion by Inducing Epithelial-to-Mesenchymal Transition","Osteosarcoma, an aggressive malignancy of long bones in children and young adults, shows poor responses to conventional chemotherapy, while distant metastasis drives most deaths. The study identifies chemokine CXCL14 as a driver of epithelial-to-mesenchymal transition (EMT) and metastatic behavior. CXCL14 is markedly higher in osteosarcoma cells than in normal osteoblasts, and silencing CXCL14 reduces migration and wound closure with epithelial marker restoration. Recombinant CXCL14 induces EMT in a dose-dependent manner, with EMT protein shifts and pathway involvement in PI3K/AKT, MAPK, and NF-κB signaling.","Ivyspring  \nInternational Publisher  \nInternationalJournal of Medical Sciences  \n2026; 23(7): 2166-2180. doi: 10.7150/ijms.127140  \nResearch Paper  \nCXCL14 promotes osteosarcoma cell migration and invasion by inducing epithelial-to-mesenchymal transition  \nChun-Han Hou1, Ming-Lung Hsu2, Chen-Hsuan Wang2, Ju-Fang Liu3􀀍, Po-Chun Chen2,4􀀍  \n1. Department of Orthopedic Surgery, National Taiwan University Hospital, Taipei 100229, Taiwan.  \n2. Department of Life Science, National Taiwan Normal University, Taipei 11677, Taiwan.  \n3. School of Oral Hygiene, College of Oral Medicine, Taipei Medical University, Taipei 10031, Taiwan.  \n4. Department of Medical Research, China Medical University Hospital, China Medical University, Taichung 404328, Taiwan.  \n􀀍 Corresponding authors: Po-Chun Chen, Assistant Professor; School of Life Science, National Taiwan Normal University, Taipei, Taiwan. No. 88, Sec. 4, Tingzhou Rd. Taipei City 11677, Taiwan (R.O.C.); Tel: 02-7749-6272; [E-mail: pcchen@ntnu.edu.tw.](E-mail: pcchen@ntnu.edu.tw. Ju-Fang Liu)[ Ju-Fang Liu](E-mail: pcchen@ntnu.edu.tw. Ju-Fang Liu); [E-mail: jufangliu@tmu.edu.tw](E-mail: jufangliu@tmu.edu.tw).  \n© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License ([https://creativecommons.org/licenses/by/4.0/](https://creativecommons.org/licenses/by/4.0/)). See [https://ivyspring.com/terms](https://ivyspring.com/terms) for full terms and conditions.  \nReceived: 2025.10.22; Accepted: 2026.02.26; Published: 2026.05.11  \nAbstract  \nOsteosarcoma, an aggressive malignancy of long bones in children and young adults, responds poorly to conventional chemotherapy, and distant metastasis remains the principal cause of death. Here we identify chemokine CXCL14 as a driver of epithelial-to-mesenchymal transition (EMT) and metastatic behavior. CXCL14 expression was markedly higher in osteosarcoma cells than in normal osteoblasts. Knockdown of CXCL14 significantly reduced cell migration and wound closure, accompanied by a shift from spindle-like to cobblestone morphology and restoration of epithelial markers. Recombinant CXCL14 promoted EMT with dose-dependent effects. Western blotting showed CXCL14 suppressed E-cadherin while elevating N-cadherin and vimentin, consistent with EMT induction. Pharmacologic and genetic inhibition revealed that PI3K/AKT, MAPK, and NF-κB signaling cascades mediate CXCL14-driven EMT. Inan orthotopic mouse model, silencing CXCL14 retarded tumor growth and reduced mesenchymal marker expression in vivo. Collectively, our results demonstrate that CXCL14 activates PI3K/AKT/MAPK/NF-κB pathways to promote EMT and osteosarcoma progression. Therapeutic targeting of CXCL14 or its downstream signaling may suppress metastasis and improve outcomes for patients with osteosarcoma. These data position CXCL14 as both a biomarker of aggressive phenotypesand an actionable molecular target in pediatric bone cancer patients, warranting preclinical and clinical validation.  \nKeywords: CXCL14; osteosarcoma; EMT; AKT; MAPK; NF-κB  \nIntroduction  \nOsteosarcoma is the most prevalent and aggressive primary bone tumor, predominantly impacting adolescents and children, with an incidence of approximately 1–3 cases per million people [1] . Osteosarcoma is highly aggressive, with a metastasis rate of approximately 20%, most commonly spreading to the lungs and other bones. Despite ongoing research, the mechanisms through which osteosarcoma develops remain unclear, although it is most likely derived from mesenchymal stem cells orosteoprogenitor cells [2] . Clinically, osteosarcoma is usually treated using chemotherapy or radiation;  \nhowever, due to the high tumor recurrence and metastasis rates to other organs, patient prognoses remain poor, with a five-year survival rate under 20% . Subsequently, most patients eventually undergo amputation surgery, making the treatment of this cancer a critical issue [3] .  \nSimilar to other solid tumors, ost","cbCairRGDxq7CsYZ","https://ap.wps.com/l/cbCairRGDxq7CsYZ","pdf",23538229,15,"English","en",105,"# Abstract\n# Keywords\n# Introduction","[{\"question\":\"What role does CXCL14 play in osteosarcoma progression?\",\"answer\":\"CXCL14 acts as a driver of epithelial-to-mesenchymal transition (EMT) and metastatic behavior, promoting osteosarcoma progression through downstream signaling pathways.\"},{\"question\":\"How does CXCL14 affect EMT markers in osteosarcoma cells?\",\"answer\":\"CXCL14 knockdown restores epithelial characteristics and reduces migration, while recombinant CXCL14 promotes EMT with suppressed E-cadherin and increased N-cadherin and vimentin.\"},{\"question\":\"Which signaling pathways mediate CXCL14-induced EMT?\",\"answer\":\"PI3K/AKT, MAPK, and NF-κB signaling cascades mediate CXCL14-driven EMT, supported by pharmacologic and genetic inhibition experiments.\"}]","CXCL14 Promotes Osteosarcoma Cell Migration and Invasion by Inducing Epithelial-to-Mesenchymal Transition | PDF",1790152768,38,[82,86,90,95],{"page_no":8,"url":83,"width":84,"height":85},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1c2193571a129fdf69a76b6ec5dbe337.webp",983,1272,{"page_no":14,"url":87,"width":88,"height":89},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ded2ba0a648af9967065c60304198f95.webp",982,1270,{"page_no":91,"url":92,"width":93,"height":94},3,"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0d0f0db4b969a6d130ee493cf435769f.webp",981,1269,{"page_no":19,"url":96,"width":97,"height":98},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ca3ca7ed24f9186091c10d5e53f3f664.webp",980,1268,{"code":4,"msg":100,"data":101},"ok",{"site_id":75,"language":74,"slug":102,"title":65,"keywords":103,"description":66,"schema_data":104,"social_meta":157,"head_meta":159,"extra_data":161,"updated_unix":162},"cxcl14-promotes-osteosarcoma-cell-migration-and-invasion-by-inducing-epithelial-to-mesenchymal-transition","",{"@graph":105,"@context":156},[106,119,139],{"@type":107,"itemListElement":108},"BreadcrumbList",[109,113,115,117],{"item":110,"name":111,"@type":112,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":114,"name":9,"@type":112,"position":14},"https://docshare.wps.com/document/",{"item":116,"name":40,"@type":112,"position":91},"https://docshare.wps.com/document/research-report/",{"item":118,"name":65,"@type":112,"position":19},"https://docshare.wps.com/document/cxcl14-promotes-osteosarcoma-cell-migration-and-invasion-by-inducing-epithelial-to-mesenchymal-transition/363712/",{"url":118,"name":65,"@type":120,"image":121,"author":126,"headline":65,"publisher":128,"fileFormat":131,"inLanguage":74,"description":66,"dateModified":132,"datePublished":133,"encodingFormat":131,"isAccessibleForFree":134,"interactionStatistic":135},"DigitalDocument",{"url":122,"@type":123,"width":124,"height":125},"https://docshare.wps.com/thumbnails/cxcl14-promotes-osteosarcoma-cell-migration-and-invasion-by-inducing-epithelial-to-mesenchymal-transition/363712.png","ImageObject",300,407,{"name":63,"@type":127},"Person",{"url":110,"name":129,"@type":130},"DocShare","Organization","application/pdf","2026-10-27","2026-09-23",true,{"@type":136,"interactionType":137,"userInteractionCount":29},"InteractionCounter",{"@type":138},"ViewAction",{"@type":140,"mainEntity":141},"FAQPage",[142,148,152],{"name":143,"@type":144,"acceptedAnswer":145},"What role does CXCL14 play in osteosarcoma progression?","Question",{"text":146,"@type":147},"CXCL14 acts as a driver of epithelial-to-mesenchymal transition (EMT) and metastatic behavior, promoting osteosarcoma progression through downstream signaling pathways.","Answer",{"name":149,"@type":144,"acceptedAnswer":150},"How does CXCL14 affect EMT markers in osteosarcoma cells?",{"text":151,"@type":147},"CXCL14 knockdown restores epithelial characteristics and reduces migration, while recombinant CXCL14 promotes EMT with suppressed E-cadherin and increased N-cadherin and vimentin.",{"name":153,"@type":144,"acceptedAnswer":154},"Which signaling pathways mediate CXCL14-induced EMT?",{"text":155,"@type":147},"PI3K/AKT, MAPK, and NF-κB signaling cascades mediate CXCL14-driven EMT, supported by pharmacologic and genetic inhibition experiments.","https://schema.org",{"og:url":118,"og:type":158,"og:title":65,"og:site_name":129,"og:description":66},"article",{"robots":160,"canonical":118},"index,follow",{"doc_id":61,"site_id":75},1791086666]